PLX8394

Plexxikon MOA PLX8394

Targeted Indication Status Sites link to clinicaltrials.gov

BRAF-mutant
tumors

Phase 1/2a

Scottsdale, AZ
Houston, TX
Detroit, MI
Salt Lake City, UT
Philadelphia, PA
Palo Alto, CA
Miami, FL
Nashville, TN
San Francisco, CA
Boston, MA
New York, NY

NCT02428712

These compounds and/or uses are investigational and have not been approved by the FDA or any other regulatory authority for the uses under investigation. Image above depicts proposed targeted pathway of the investigational agent(s) in the targeted indication.

Zhang C et al. Nature Letters. 2015; 526; 583-6.
Data on file.